Related Experiment Video
Updated: Aug 6, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
The AGO2 adaptor LIMD1 expands the functional and evolutionary reach of microRNA targeting
Alex F F Crozier1, Kunal M Shah1, Paul Grevitt1
1Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Abstract:
MicroRNA (miRNA) silencing is classically ascribed to RNA-sequence rules that guide Argonaute 2 (AGO2) targeting. Using chimeric eCLIP and complementary analyses in CRISPR-edited human lung epithelial cells, we show that efficient miRNA targeting also depends on the AGO2 adaptor-scaffold LIMD1. In LIMD1-deficient cells, AGO2 binds more miRNAs, but each AGO2-miRNA engages fewer transcripts and sites, reducing occupancy and halving both the breadth and depth of targeting. LIMD1 dependence is most pronounced for poorly conserved, weakly seed-paired sites that nonetheless form stable duplexes. LIMD1 deficiency alters AGO2 footprints and derepresses oncogenic targets inversely correlated with LIMD1 expression in lung adenocarcinoma. Thus, LIMD1 modifies the outcome of sequence-defined interactions that would otherwise be infrequent, unstable, or unproductive, revealing an adaptor-governed layer of posttranscriptional regulation beyond RNA-sequence rules.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
